Glioblastoma: Radiation treatment margins, how small is large enough?

Standard treatment for glioblastoma consists of surgical resection followed by radiation therapy with concurrent and adjuvant chemotherapy. Conventional radiation clinical treatment volumes include a 2- to 3-cm margin around magnetic resonance imaging or computed tomography enhancing abnormalities in the brain as well as a margin around the T2 or fluid-attenuated inversion recovery abnormality. However, there remains significant variability with respect to whether such extensive margins are necessary. Collectively, we as authors of this manuscript also use different margins, with A.G.W. employing European Organization for Research and Treatment of Cancer recommendations of a 2- to 3-cm margin on T1 enhancement for 60 Gy and M.P.M. using Radiation Therapy Oncology Group recommendations of 2 cm on T2 signal abnormality for the initial 46 Gy and 2.5-cm margin on T1 enhancement for a 14-Gy boost. Our experiences reflect the heterogeneity of margin definition and selection for this disease and underscore an important area of further research to minimize this variability. In this article, we review studies exploring recurrence patterns and outcomes in patients treated using both conventional and more limited margins. We conclude that treating to "smaller" margins does not alter recurrence patterns nor does it result in inferior survival, but whether this is because of the inherently limited benefit of radiation therapy in the first place, or whether it is truly because microscopic tumor control at larger distances is not an issue, remains unestablished.

[1]  K. Hess,et al.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. , 2009, The Lancet. Oncology.

[2]  C. Brennan,et al.  Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma , 2014, Clinical Cancer Research.

[3]  M. Ogura,et al.  Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution , 2013, Radiation oncology.

[4]  D. Bigner,et al.  Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function , 2007, Clinical Cancer Research.

[5]  R L Ehman,et al.  Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. , 1988, Radiology.

[6]  W. Curran,et al.  Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. , 2009, International journal of radiation oncology, biology, physics.

[7]  W. Yung,et al.  Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  S. Janelidze,et al.  Cure of established GL261 mouse gliomas after combined immunotherapy with GM‐CSF and IFNγ is mediated by both CD8+ and CD4+ T‐cells , 2009, International journal of cancer.

[9]  W. Dandy,et al.  REMOVAL OF RIGHT CEREBRAL HEMISPHERE FOR CERTAIN TUMORS WITH HEMIPLEGIA: PRELIMINARY REPORT , 1928 .

[10]  P. Wen,et al.  Glioma Therapy in Adults , 2006, The neurologist.

[11]  A. Krishnan,et al.  Evidence that MR diffusion tensor imaging (tractography) predicts the natural history of regional progression in patients irradiated conformally for primary brain tumors. , 2008, International journal of radiation oncology, biology, physics.

[12]  G. Linette,et al.  Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma. , 2015, International journal of radiation oncology, biology, physics.

[13]  Christopher M. Jackson,et al.  Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model , 2014, PloS one.

[14]  A. Brandes,et al.  Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Sarkaria,et al.  North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. , 2011, International journal of radiation oncology, biology, physics.

[16]  Karl-Josef Langen,et al.  O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. , 2005, Brain : a journal of neurology.

[17]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[18]  J. Markert,et al.  Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide , 2011, Journal of medical imaging and radiation oncology.

[19]  Fred H. Hochberg,et al.  Assumptions in the radiotherapy of glioblastoma , 1980, Neurology.

[20]  C. Drake,et al.  Sustained CD4+ T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide , 2014, Oncoimmunology.

[21]  B A Kall,et al.  Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. , 1987, Journal of neurosurgery.

[22]  B. Fisher,et al.  Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. , 1992, International journal of radiation oncology, biology, physics.

[23]  K. Walter,et al.  Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. , 2010, International journal of radiation oncology, biology, physics.

[24]  M. Gilbert,et al.  Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial , 2008, Cancer Chemotherapy and Pharmacology.

[25]  S. Grossman,et al.  Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas. , 2012, CNS oncology.

[26]  E C Halperin,et al.  Radiation therapy treatment planning in supratentorial glioblastoma multiforme: an analysis based on post mortem topographic anatomy with CT correlations. , 1989, International journal of radiation oncology, biology, physics.

[27]  Isabelle Salmon,et al.  Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  Robert G. Selker,et al.  Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma , 2009 .

[29]  S B Green,et al.  Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. , 1989, Journal of neurosurgery.

[30]  F Giangaspero,et al.  Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. , 1983, Journal of neurosurgery.

[31]  E. Alexander,et al.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.

[32]  F. Wenz,et al.  Memory function before and after whole brain radiotherapy in patients with and without brain metastases. , 2008, International journal of radiation oncology, biology, physics.

[33]  J. Markert,et al.  Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide , 2014, Radiation oncology.

[34]  T. Nishidai,et al.  Radiation therapy in the treatment of glioblastoma. , 1976, AJR. American journal of roentgenology.

[35]  D. Amelio,et al.  Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[36]  J. Shinoda,et al.  Hypofractionated High-Dose Irradiation with Positron Emission Tomography Data for the Treatment of Glioblastoma Multiforme , 2014, BioMed research international.

[37]  W. Mason,et al.  Canadian recommendations for the treatment of glioblastoma multiforme , 2007, Current oncology.

[38]  Karl Herholz,et al.  Delineation of Brain Tumor Extent with [11C]l-Methionine Positron Emission Tomography , 2004, Clinical Cancer Research.

[39]  I. Maclennan,et al.  Analysis of treatment in childhood leukemia. IV. The critical association between dose fractionation and immunosuppression induced by cranial irradiation , 1978, Cancer.

[40]  Walter J Curran,et al.  Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  J D Pickard,et al.  Diffusion tensor imaging: possible implications for radiotherapy treatment planning of patients with high-grade glioma. , 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

[42]  Karl Herholz,et al.  Brain Tumor Extent with [11C]-L-methionine Positron Emission Tomography: Local Comparison with Stereotactic Histopatholoy. , 2004 .

[43]  John Wong,et al.  Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. , 2013, International journal of radiation oncology, biology, physics.

[44]  C. Degueldre,et al.  Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[45]  V. Esposito,et al.  A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma. , 2010, International journal of radiation oncology, biology, physics.

[46]  Tracy T Batchelor,et al.  Standard chemoradiation for glioblastoma results in progressive brain volume loss , 2015, Neurology.

[47]  S. Piantadosi,et al.  Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide , 2011, Clinical Cancer Research.

[48]  T. Greitz,et al.  Localized shaped field radiotherapy of malignant glioblastoma multiforme. , 1976, International journal of radiation oncology, biology, physics.

[49]  Shiao Y. Woo,et al.  Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. , 2007, International journal of radiation oncology, biology, physics.

[50]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.